The advent of specific DOAC reversal agents necessitates the development of standardized, multidisciplinary institutional protocols for managing severe bleeding and urgent surgical emergencies.
Answers are grounded in this paper and cite their sources.
Institutions must implement standardized DOAC reversal protocols now; reinforces Level 1 guideline consensus for emergency care.
Anticoagulation is the cornerstone of prevention and treatment of venous thromboembolism (VTE) and stroke prevention in patients with atrial fibrillation (AF). However, the mechanisms by which anticoagulants confer therapeutic benefit also increase the risk of bleeding. As such, reversal strategies are critical. Until recently, the direct oral anticoagulants (DOACs) dabigatran, rivaroxaban, apixaban, and edoxaban lacked a specific reversal agent. This report is based on findings from the Anticoagulation Education Task Force, which brought together patient groups and professionals representing different medical specialties with an interest in patient safety and expertise in AF, VTE, stroke, anticoagulation, and reversal agents, to discuss the current status of anticoagulation reversal and fundamental changes in management of bleeding associated with DOACs occasioned by the approval of idarucizumab, a specific reversal agent for dabigatran, as well as recent clinical data on specific reversal agents for factor Xa inhibitors. Recommendations are given for when there is a definite need for a reversal agent (e.g. in cases of life-threatening bleeding, bleeding into a closed space or organ, persistent bleeding despite local haemostatic measures, and need for urgent interventions and/or interventions that carry a high risk for bleeding), when reversal agents may be helpful, and when a reversal agent is generally not needed. Key stakeholders who require 24-7/around-the-clock access to these agents vary among hospitals; however, from a practical perspective the emergency department is recommended as an appropriate location for these agents. Clearly, the advent of new agents requires standardised protocols for treating bleeding on an institutional level.
No takes yet. Share an insight, caveat, or question.
Büller et al. (2016) conducted a review in Bleeding associated with direct oral anticoagulants (DOACs). DOAC reversal agents (idarucizumab, andexanet alfa) was evaluated. Specific reversal agents for direct oral anticoagulants, such as idarucizumab and andexanet alfa, provide rapid reversal of anticoagulant effects in emergency situations, necessitating standardized institutional protocols.
Synapse has enriched 10 related papers. Consider them for comparative context: